Enanta Pharmaceuticals to Participate at Evercore ISI HealthCONx Conference

Rhea-AI Summary

Enanta Pharmaceuticals, Inc. (ENTA) announced that its President and CEO, Dr. Jay R. Luly, will participate in a fireside chat at Evercore ISI HealthCONx Conference on November 29, 2023. The event will be live webcasted and accessible through the company's website. A replay will also be available for at least 30 days.

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at Evercore ISI HealthCONx Conference on November 29, 2023 at 7:55 a.m. ET in Miami, FL.

A live webcast of the event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com. A replay of the webcast will be available following the presentation and will be archived for at least 30 days.

About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on treatments for viral infections. Enanta’s research and development programs include clinical candidates for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV).

A portion of Enanta’s royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie contribute to the ongoing funding of Enanta’s operations. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic HCV infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET^® (U.S.) and MAVIRET^® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231122012068/en/

Media and Investors

Jennifer Viera

617-744-3848

jviera@enanta.com

Source: Enanta Pharmaceuticals, Inc.

FAQ

What is the name of the company participating in the Evercore ISI HealthCONx Conference on November 29, 2023?

Enanta Pharmaceuticals, Inc. (ENTA)

Who will be participating in the fireside chat at the conference?

Dr. Jay R. Luly, President and CEO of Enanta Pharmaceuticals, Inc.

When and where will the fireside chat take place?

The fireside chat will take place on November 29, 2023, at 7:55 a.m. ET in Miami, FL.

How can I access the live webcast of the event?

The live webcast will be accessible by visiting the 'Events and Presentations' section on the 'Investors' page of Enanta's website at www.enanta.com.

Will there be a replay of the webcast available?

Yes, a replay of the webcast will be available following the presentation and will be archived for at least 30 days.